NeoGenomics, Inc. (NEO) experienced a pre-market plunge of 7.7% on Tuesday, February 18, as the company's fourth-quarter results fell short of analysts' expectations.
In its latest earnings report, NeoGenomics posted a quarterly loss per share of $0.12, missing the consensus estimate of $0.03 earnings per share. The company's revenue for the quarter came in at $172 million, slightly below the FactSet projection of $173.2 million.
Despite the disappointing quarterly performance, NeoGenomics reaffirmed its full-year 2025 guidance, which projects earnings per share of $0.20 and revenue of $733 million. However, investors seemed to focus more on the near-term disappointment, sending the stock tumbling in pre-market trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.